Summit Therapeutics (SMMT) reported a Q4 non-GAAP net loss Monday of $0.07 per diluted share, widening from a loss of $0.04 a year earlier.
Analysts polled by FactSet expected a loss of $0.08.
The biopharmaceutical company did not report any revenue.
The company reported cash, cash equivalents and short-term investments of $412.3 million as of Dec. 31, up from $186.2 million a year earlier.
Summit shares were up nearly 11% in recent premarket activity
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。